Eiger BioPharmaceuticals, Inc.
EIGR
주식 순위
#36456
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
주가
$1.73
마지막 동기화: 2025-06-17
시가총액
$2.55M
변동 (1일)
-0.29%
변동 (1년)
-79.71%
국가
US
거래 Eiger BioPharmaceuticals, Inc. (EIGR)
카테고리
Healthcare
Eiger BioPharmaceuticals, Inc. (EIGR)의 EPS
December 2023 기준 EPS TTM: $-50.79
Eiger BioPharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-50.79입니다. 2022년 말에는 회사의 EPS가 $-69.74였으며, 이는 2021년의 EPS $-29.98와 증가입니다.
Eiger BioPharmaceuticals, Inc.의 EPS 기록 (2016 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-50.79 | 0.02% |
| 2023 | $-50.78 | -27.19% |
| 2022 | $-69.74 | 132.62% |
| 2021 | $-29.98 | -56.76% |
| 2020 | $-69.34 | -25.04% |
| 2019 | $-92.50 | -19.31% |
| 2018 | $-114.63 | -21.43% |
| 2017 | $-145.90 | -37.96% |
| 2016 | $-235.16 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -134.10% |
US
|
|
| $-7.98 | -84.29% |
US
|
|
| $-5.29 | -89.58% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -154.62% |
NL
|
